WuXi Biologics (Cayman) Inc. (HKG:2269)

WuXi Biologics Statistics

Total Valuation

WuXi Biologics has a market cap or net worth of HKD 133.89 billion. The enterprise value is 126.28 billion.

Market Cap	133.89B
Enterprise Value	126.28B

Important Dates

The last earnings date was Tuesday, March 24, 2026.

Earnings Date	Mar 24, 2026
Ex-Dividend Date	n/a

Share Statistics

WuXi Biologics has 4.14 billion shares outstanding. The number of shares has decreased by -1.22% in one year.

Current Share Class	4.14B
Shares Outstanding	4.14B
Shares Change (YoY)	-1.22%
Shares Change (QoQ)	-0.48%
Owned by Insiders (%)	1.28%
Owned by Institutions (%)	35.99%
Float	3.73B

Valuation Ratios

The trailing PE ratio is 25.05 and the forward PE ratio is 19.56. WuXi Biologics's PEG ratio is 1.22.

PE Ratio	25.05
Forward PE	19.56
PS Ratio	5.52
PB Ratio	2.27
P/TBV Ratio	2.66
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	1.22

Enterprise Valuation

EV / Earnings	23.12
EV / Sales	5.21
EV / EBITDA	14.35
EV / EBIT	17.07
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.39, with a Debt / Equity ratio of 0.06.

Current Ratio	3.39
Quick Ratio	2.96
Debt / Equity	0.06
Debt / EBITDA	0.39
Debt / FCF	n/a
Interest Coverage	46.46

Financial Efficiency

Return on equity (ROE) is 11.64% and return on invested capital (ROIC) is 12.99%.

Return on Equity (ROE)	11.64%
Return on Assets (ROA)	6.88%
Return on Invested Capital (ROIC)	12.99%
Return on Capital Employed (ROCE)	12.00%
Weighted Average Cost of Capital (WACC)	6.91%
Revenue Per Employee	1.83M
Profits Per Employee	412,168
Employee Count	13,252
Asset Turnover	0.36
Inventory Turnover	8.11

Taxes

In the past 12 months, WuXi Biologics has paid 1.70 billion in taxes.

Income Tax	1.70B
Effective Tax Rate	21.00%

Stock Price Statistics

The stock price has increased by +23.51% in the last 52 weeks. The beta is 0.50, so WuXi Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.50
52-Week Price Change	+23.51%
50-Day Moving Average	37.34
200-Day Moving Average	33.89
Relative Strength Index (RSI)	38.24
Average Volume (20 Days)	31,846,067

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, WuXi Biologics had revenue of HKD 24.25 billion and earned 5.46 billion in profits. Earnings per share was 1.29.

Revenue	24.25B
Gross Profit	11.15B
Operating Income	7.40B
Pretax Income	8.08B
Net Income	5.46B
EBITDA	8.80B
EBIT	7.40B
Earnings Per Share (EPS)	1.29

Balance Sheet

The company has 17.51 billion in cash and 3.45 billion in debt, with a net cash position of 14.05 billion or 3.40 per share.

Cash & Cash Equivalents	17.51B
Total Debt	3.45B
Net Cash	14.05B
Net Cash Per Share	3.40
Equity (Book Value)	59.02B
Book Value Per Share	12.72
Working Capital	22.06B

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	1.43B
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 45.98%, with operating and profit margins of 30.50% and 22.53%.

Gross Margin	45.98%
Operating Margin	30.50%
Pretax Margin	33.30%
Profit Margin	22.53%
EBITDA Margin	36.30%
EBIT Margin	30.50%
FCF Margin	n/a

Dividends & Yields

WuXi Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.22%
Shareholder Yield	1.22%
Earnings Yield	4.08%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on November 16, 2020. It was a forward split with a ratio of 3.

Last Split Date	Nov 16, 2020
Split Type	Forward
Split Ratio	3

Scores

Altman Z-Score	n/a
Piotroski F-Score	6